Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
Allelic losses occurring in cancer cells have been suggested as potential targets for therapy. Here, the authors show how recurring loss of heterozygosity of a drug metabolic gene in colorectal cancers can be exploited using a low molecular weight compound.
Guardado en:
Autores principales: | Veronica Rendo, Ivaylo Stoimenov, André Mateus, Elin Sjöberg, Richard Svensson, Anna-Lena Gustavsson, Lars Johansson, Adrian Ng, Casey OʼBrien, Marios Giannakis, Per Artursson, Peter Nygren, Ian Cheong, Tobias Sjöblom |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f0524ece03f240dd980cb46a0462a392 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
por: Veronica Rendo, et al.
Publicado: (2020) -
Exchange catalysis by tapasin exploits conserved and allele-specific features of MHC-I molecules
por: Huan Lan, et al.
Publicado: (2021) -
Improved haplotype inference by exploiting long-range linking and allelic imbalance in RNA-seq datasets
por: Emily Berger, et al.
Publicado: (2020) -
Exploiting sorghum genetic diversity for enhanced aluminum tolerance: Allele mining based on the Alt SB locus
por: Barbara Hufnagel, et al.
Publicado: (2018) -
Developmental stability covaries with genome-wide and single-locus heterozygosity in house sparrows.
por: Carl Vangestel, et al.
Publicado: (2011)